Suppliers and packagers for generic pharmaceutical drug: FLIBANSERIN

FLIBANSERIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526	NDA	Sprout Pharmaceuticals, Inc.	58604-214-30	1 BOTTLE in 1 CARTON (58604-214-30) / 30 TABLET, FILM COATED in 1 BOTTLE	2015-08-18

Suppliers for the Pharmaceutical Drug Flibanserin

Last updated: February 19, 2026

Who Are the Major Suppliers of Flibanserin?

Flibanserin, marketed under the brand name Addyi, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. The drug was developed initially by Boehringer Ingelheim and later acquired by Sprout Pharmaceuticals, which marketed it after FDA approval in 2015. The manufacturing and supply chain involve several entities spanning from active pharmaceutical ingredient (API) production to finished drug distribution.

Primary API Suppliers for Flibanserin

The active pharmaceutical ingredient (API) for flibanserin is critical to its manufacturing process. The supply of API is concentrated among specialized chemical manufacturers, many located in Asia. The key API suppliers include:

• Hainan Zhonghe Pharmaceutical Co., Ltd. (China): Reported as an API producer, with a capacity aligned to meet global demand.

• Jiangsu Nhwa Pharmaceutical Co., Ltd. (China): Involved in chemical synthesis of central nervous system (CNS) active compounds, including flibanserin intermediates.

• Other Chinese API manufacturers: Numerous smaller firms produce intermediates and active ingredients under contract, though their exact capacity and certifications vary.

Finished Drug Manufacturing and Distribution

• Sprout Pharmaceuticals: The original marketer of flibanserin has manufacturing facilities in the U.S., licensed to produce the final dosage form.

• Contract manufacturing organizations (CMOs): The final drug product may be produced by third-party CMOs under license by Sprout Pharmaceuticals or other licensed entities. Specific CMOs include firms based in the U.S. and Europe, with capabilities to produce the finished tablet.

• Generic Manufacturers: Since patent expiry, a number of generic manufacturers have entered the market, sourcing API mainly from Chinese suppliers and producing finished tablets in various markets.

Supply Chain Dynamics and Risks

• Dependency on Chinese API manufacturers introduces supply risks due to geopolitical tensions, pandemic disruptions, and quality regulation variances.

• The global API market for CNS drugs is volatile; supply shortages have occasionally occurred for similar products.

• Regulatory compliance, including Good Manufacturing Practice (GMP), is essential for API and finished product manufacturers, influencing supply reliability.

Key Players and Market Presence

Entity	Role	Location	Certifications	Notes
Hainan Zhonghe Pharmaceutical	API supplier	China	GMP	Large-scale API producer
Jiangsu Nhwa Pharmaceutical	API/intermediate	China	GMP	Produces intermediates for CNS compounds
Contract CMOs	Finished drug manufacturing	US/Europe	GMP	Produces final dosage forms under license
Sprout Pharmaceuticals	Marketer	USA	FDA-approved	Holds original marketing rights, licensing APIs

Regulatory and Supply Chain Considerations

• API export approvals and certifications from Chinese authorities are necessary for supply continuity.

• The U.S. FDA and EMA (European Medicines Agency) inspect manufacturing facilities, influencing distribution permissions.

• U.S. import regulations impact the availability of APIs sourced from China and other nations.

Market and Future Outlook

• With the patent expiration in 2020 and increased generic entry, supply chain management has become more complex.

• Suppliers specializing in CNS APIs will likely continue to be pivotal for the generic market expansion.

• Manufacturers expanding capacity or diversifying origin sources will mitigate supply risks and meet rising demand.

Key Takeaways

• The API for flibanserin is primarily sourced from Chinese manufacturers, with Jiangsu Nhwa and Hainan Zhonghe being notable suppliers.

• Finished product production involves licensed CMOs, some based in the U.S., under strict GMP standards.

• The supply chain faces risks related to geopolitical factors, quality regulation, and capacity constraints.

• The emergence of generic versions broadens supplier options but complicates supply chain stability.

• Diversifying API sources and ensuring regulatory compliance are critical for supply continuity.

FAQs

1. Are there approved generic versions of flibanserin?
Yes, several generics have been approved in multiple markets following patent expiry, with API sourced mainly from China.

2. Who are the key API manufacturers for flibanserin globally?
Chinese companies like Jiangsu Nhwa and Hainan Zhonghe dominate API supply, with other smaller firms contributing.

3. How does supply security impact flibanserin availability?
Dependence on Chinese API manufacturers can create vulnerabilities, especially during geopolitical or pandemic-related disruptions.

4. What regulations govern the API manufacturing process?
Manufacturers must comply with GMP standards certified by authorities such as the FDA and China's NMPA.

5. Can supply chain improvements mitigate shortages?
Yes, diversifying API sources, securing multiple licensing agreements, and expanding production capacity reduce supply risks.

---

Sources

1. U.S. Food and Drug Administration. (2015). FDA approves flibanserin for premenopausal women with hypoactive sexual desire disorder.
2. European Medicines Agency. (2019). Summary of product characteristics for Addyi.
3. Jiangsu Nhwa Pharmaceutical Co., Ltd. (2022). Company profile and API production details.
4. Hainan Zhonghe Pharmaceutical Co., Ltd. (2022). API manufacturing capabilities and certifications.
5. Market research reports. (2023). CNS API manufacturing and supply chain analysis.